Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 6;11(21):6574.
doi: 10.3390/jcm11216574.

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Esther Hazane Leroyer  1 , Caroline Ziegler  1 , Charline Moulin  1 , Arnaud Campidelli  1 , Caroline Jacquet  1 , Marie Thérèse Rubio  1   2 , Pierre Feugier  1   3 , Simona Pagliuca  1   2
Affiliations
Review

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Esther Hazane Leroyer et al. J Clin Med. .

Abstract

Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20-30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders is more than evident in this disease because anti-CD30 antibodies and checkpoint inhibitors have been able to rescue patients previously remaining without therapeutic options. Autologous hematopoietic cell transplantation still represents a significant step in the treatment algorithm for chemosensitive HL; however, the possibility to induce complete responses after allogeneic transplant procedures in patients receiving reduced-intensity conditioning regimens informs on its sensitivity to immunological control. Furthermore, the investigational application of adoptive T cell transfer therapies paves the way for future indications in this setting. Here, we seek to provide a fresh and up-to-date overview of the new immunotherapeutic agents dominating the scene of relapsed/refractory HL. In this optic, we will also review all the potential molecular mechanisms of tumor resistance, theoretically responsible for treatment failures, and we will discuss the place of allogeneic stem cell transplantation in the era of novel therapies.

Keywords: CAR-T cells; Hodgkin Lymphoma; immune escape; immunotherapy; mechanisms of resistance.

PubMed Disclaimer

Conflict of interest statement

This research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Incidence and mortality of HL (cumulative rate per 100,000) grouped by sex across the time. Lines are smoothed by the locally weighted linear regression (LOESS) algorithm. Rates are shown on a semi-logarithmic scale. (B) Incidence and mortality of HL (rate per 100,000) by sex across ages. Rates are shown on a semi-logarithmic scale. (C) Relationship between incidence and mortality across countries (indicated as an age-standardized rate -ASR). (D) Map showing the estimated crude incidence rates in 2020, for HL in both sexes and across all ages. Data used to generate this figure were extracted from the Global Cancer Observatory project (International Agency for Research on Cancer).
Figure 2
Figure 2
Timeline history of FDA approvals in Hodgkin lymphoma.
See this image and copyright information in PMC

References

    1. Connors J.M., Cozen W., Steidl C., Carbone A., Hoppe R.T., Flechtner H.-H., Bartlett N.L. Hodgkin lymphoma. Nat. Rev. Dis. Prim. 2020;6:61. doi: 10.1038/s41572-020-0189-6. - DOI - PubMed
    1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed
    1. Meyer R.M., Gospodarowicz M.K., Connors J.M., Pearcey R.G., Wells W.A., Winter J.N., Horning S.J., Dar A.R., Shustik C., Stewart D.A., et al. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin’s Lymphoma. N. Engl. J. Med. 2012;366:399–408. doi: 10.1056/NEJMoa1111961. - DOI - PMC - PubMed
    1. Straus D.J., Jung S.-H., Pitcher B., Kostakoglu L., Grecula J.C., Hsi E.D., Schöder H., Popplewell L.L., Chang J.E., Moskowitz C.H., et al. CALGB 50604: Risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018;132:1013–1021. doi: 10.1182/blood-2018-01-827246. - DOI - PMC - PubMed
    1. Sasse S., Bröckelmann P.J., Goergen H., Plütschow A., Müller H., Kreissl S., Buerkle C., Borchmann S., Fuchs M., Borchmann P., et al. Long-Term Follow-UP of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. JCO. 2017;35:1999–2007. doi: 10.1200/JCO.2016.70.9410. - DOI - PubMed

LinkOut - more resources